FacebookTwitterGoogle+RedditEmail

Son of Neurontin Meets the Fibromyalgia Epidemic

by MARTHA ROSENBERG

Who says technology transfer doesn’t pay?

Pregablin, discovered by Northwestern University chemist Richard Silverman in 1989 to become Pfizer’s Lyrica, earned the university a cool $700 million when it sold royalties in Dec. 2007.

The nerve pain-cum-seizure pill is funding the $100 million Richard and Barbara Silverman Hall for Molecular Therapeutics & Diagnostics–currently a hole in the ground on the way to the student union–which will employ 245 this fall. Views of Lake Michigan and the duck pond included.

And, thanks to FDA approval in 2007 of Lyrica as the first US drug for the pain condition fibromyalgia, it may earn as much as its molecular relative–Pfizer’s Neurontin (gabapentin)–which made $3 billion a year before its patent ran out in 2004.

No wonder they call Lyrica son of Neurontin.

Of course there have been setbacks on the road to marketing Lyrica.

In 2001, Pfizer had to freeze pain trials and restrict pregablin in patients when test mice developed cancerous tumors. Profit warning! But when rats tests were okay, Toni Hoover, a vice president with Pfizer’s now defunct Ann Arbor, MI labs sounded the all clear. “The FDA has found that the benefit of taking the drug outweighs any risk,” she told the Detroit News.

Pfizer brass failed to embrace Silverman the way it embraced the $564 million he made for them in Lyrica’s first three months. (“They had a launch party for the drug, and I asked to come. Nope. No party for me. They take your stuff and tell you to go away,” he told the Chicago Tribune.)

And Lyrica’s not approved for the “social phobia” detailed in Pfizer original marketing plans. Yet.

But as long as pharma can get a drug approved in advance of its uses and people will take an antipsychotic for the blues or a seizure med for migraines, Lyrica has a future.

Initial articles about Lyrica which, like Neurontin, is an anti-seizure drug that modulates calcium channels to dampen the excitability of nerve endings, were positive.

“Well tolerated,” said Arthritis and Rheumatism in 2005.

“Proven efficacy” and “No new adverse events,” said Drugs of Today in 2005 and 2007.

“Durability of effect for relieving FM pain,” said the journal Pain in 2008.

Unfortunately the articles were all written by Pfizer paid doctors.

Actual users of Lyrica report memory loss, mental confusion, extreme weight gain, hair loss, impaired driving, disorientation, twitching and a lot of I’d-rather-have-my-fibro-symptoms-back-if-this-is-the-cure on askapatient.com. P.S. There are two deaths.

Of course its no secret that Pfizer’s blockbusters Viagra, Zoloft and Lipitor are history and its pipeline is bare. In January, it announced it was losing 800 of its researchers and buying Wyeth (no danger of getting new researchers there.)

Nor can its gravy train of antibiotics in food animals–pun intended–last much longer with residues found in meat, water and even crops and world recognition of antibiotic resistance.

Just as people were forgetting that Pfizer paid $430 million in 2004 for criminally promoting Neurontin for bipolar disorder, attention-deficit disorder, restless legs syndrome and other unapproved disorders, an article in the January 9 New England Journal of Medicine titled “The Neurontin Legacy–Marketing through Misinformation and Manipulation,” shows it’s déjà vu all over again at Pfizer.

Nor is Lyrica the only game in town anymore for fibromyalgia since the FDA approved Lilly’s antidepressant Cymbalta in 2008 and Forest Laboratories’ antidepressant Savella in January. Now Americans can choose between an antidepressant with a black box warning for suicide and a seizure medication for a disease they didn’t know they had–or was an epidemic–ten years ago.

Lyrica itself was slated for an FDA black box suicide warning in 2008. A 92-page appeal from Pfizer last summer called the suicide stats “an exaggeration of risk that is introduced by ascertainment bias” and cautioned against “overwarning…patients and prescribers” so that they “underestimate the risks of declining treatment.” Especially risks for Pfizer.

As Northwestern students negotiate the snow and construction at the future home of the Richard and Barbara Silverman Hall for Molecular Therapeutics & Diagnostics, any pain they feel is from all-nighters, all-you-can-drink nights and the cold–not fibromyalgia. Few will remember Lyrica when classes start in the new science hall. Nor can a building be withdrawn.

MARTHA ROSENBERG is a columnist/cartoonist who writes about public health. She can be reached  at martharosenberg@sbcglobal.net

 

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

February 08, 2016
Paul Craig Roberts – Michael Hudson
Privatization: the Atlanticist Tactic to Attack Russia
Mumia Abu-Jamal
Water War Against the Poor: Flint and the Crimes of Capital
John V. Walsh
Did Hillary’s Machine Rig Iowa? The Highly Improbable Iowa Coin Tosses
Vincent Emanuele
The Curse and Failure of Identity Politics
Eliza A. Webb
Hillary Clinton’s Populist Charade
Uri Avnery
Optimism of the Will
Roy Eidelson Trudy Bond, Stephen Soldz, Steven Reisner, Jean Maria Arrigo, Brad Olson, and Bryant Welch
Preserve Do-No-Harm for Military Psychologists: Coalition Responds to Department of Defense Letter to the APA
Patrick Cockburn
Oil Prices and ISIS Ruin Kurdish Dreams of Riches
Binoy Kampmark
Julian Assange, the UN and Meanings of Arbitrary Detention
Shamus Cooke
The Labor Movement’s Pearl Harbor Moment
W. T. Whitney
Cuba, War and Ana Belen Montes
Jim Goodman
Congress Must Kill the Trans Pacific Partnership
Peter White
Meeting John Ross
Colin Todhunter
Organic Agriculture, Capitalism and the Parallel World of the Pro-GMO Evangelist
Ralph Nader
They’re Just Not Answering!
Cesar Chelala
Beware of the Harm on Eyes Digital Devices Can Cause
Weekend Edition
February 5-7, 2016
Jeffrey St. Clair
When Chivalry Fails: St. Bernard and the Machine
Leonard Peltier
My 40 Years in Prison
John Pilger
Freeing Julian Assange: the Final Chapter
Garry Leech
Terrifying Ted and His Ultra-Conservative Vision for America
Andrew Levine
Smash Clintonism: Why Democrats, Not Republicans, are the Problem
William Blum
Is Bernie Sanders a “Socialist”?
Daniel Raventós - Julie Wark
We Can’t Afford These Billionaires
Enrique C. Ochoa
Super Bowl 50: American Inequality on Display
Jonathan Cook
The Liberal Hounding of Julian Assange: From Alex Gibney to The Guardian
George Wuerthner
How the Bundy Gang Won
Mike Whitney
Peace Talks “Paused” After Putin’s Triumph in Aleppo 
Ted Rall
Hillary Clinton: the Good, the Bad and the Ugly
Gary Leupp
Is a “Socialist” Really Unelectable? The Potential Significance of the Sanders Campaign
Vijay Prashad
The Fault Line of Race in America
Eoin Higgins
Please Clap: the Jeb Bush Campaign Pre-Mortem
Joseph Mangano – Janette D. Sherman
The Invisible Epidemic: Radiation and Rising Rates of Thyroid Cancer
Andre Vltchek
Europe is Built on Corpses and Plunder
Jack Smith
Obama Readies to Fight in Libya, Again
Robert Fantina
As Goes Iowa, So Goes the Nation?
Dean Baker
Market Turmoil, the Fed and the Presidential Election
John Grant
Israel Moves to Check Its Artists
John Wight
Who Was Cecil Rhodes?
David Macaray
Will There Ever Be Anyone Better Than Bernie Sanders?
Christopher Brauchli
Suffer Little Children: From Brazil to Flint
JP Sottile
Did Fox News Help the GOP Establishment Get Its Groove Back?
Binoy Kampmark
Legalizing Cruelties: the Australian High Court and Indefinite Offshore Detention
John Feffer
Wrestling With Iran
Rob Prince – Ibrahim Kazerooni
Syria Again
Louisa Willcox
Park Service Finally Stands Up for Grizzlies and Us
FacebookTwitterGoogle+RedditEmail